CCN3 promotes prostate cancer bone metastasis by modulating the tumor-bone microenvironment through RANKL-dependent pathway (Q39174534)

9 September 2017

CCN3 promotes prostate cancer bone metastasis by modulating the tumor-bone microenvironment through RANKL-dependent pathway (English)

1 reference

9 September 2017

1 reference

Po-Chun Chen

1

1 reference

9 September 2017

Hsu-Chen Cheng

series ordinal

2

1 reference

9 September 2017

Chih-Hsin Tang

series ordinal

3

1 reference

9 September 2017

language of work or name

English

0 references

publication date

27 March 2013

1 reference

9 September 2017

1 reference

9 September 2017

34

1 reference

9 September 2017

7

1 reference

9 September 2017

1669-1679

1 reference

Screening for prostate cancer: an update

9 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT103

Prostate cancer bone metastases promote both osteolytic and osteoblastic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT103

Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT103

Zoledronic acid preserves bone structure and increases survival but does not limit tumour incidence in a prostate cancer bone metastasis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT103

The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT103

Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT103

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT103

Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT103

Secretion of IL-6 and IL-8 from lysophosphatidic acid-stimulated oral squamous cell carcinoma promotes osteoclastogenesis and bone resorption.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT103

A structural approach to the role of CCN (CYR61/CTGF/NOV) proteins in tumourigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT103

Functions and mechanisms of action of CCN matricellular proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT103

Prognostic value of CCN3 in osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT103

Prognostic relevance of CCN3 in Ewing sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT103

Downregulation of CCN3 expression as a potential mechanism for melanoma progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT103

Impact of CCN3 (NOV) glycosylation on migration/invasion properties and cell growth of the choriocarcinoma cell line Jeg3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT103

Nephroblastoma overexpressed gene (NOV) enhances cell motility and COX-2 upregulation of human osteosarcoma involves αvβ5 integrin, ILK and AP-1-dependent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT103

Differential expression of the ccn3 (nov) proto-oncogene in human prostate cell lines and tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT103

CCN3 increases cell motility and ICAM-1 expression in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT103

Attenuation of bone mass and increase of osteoclast formation in decoy receptor 3 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT103

Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT103

Transcriptional program of mouse osteoclast differentiation governed by the macrophage colony-stimulating factor and the ligand for the receptor activator of NFkappa B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT103

CCN3 increases cell motility and MMP-13 expression in human chondrosarcoma through integrin-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT103

Osteoblasts in prostate cancer metastasis to bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT103

The RANK/RANKL/OPG triad in cancer-induced bone diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT103

Metastasis to bone: causes, consequences and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT103

CCN3--a key regulator of the hematopoietic compartment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT103

The evolving biology and treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT103

The "emigration, migration, and immigration"of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT103

Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT103

RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT103

The tumor microenvironment and its contribution to tumor evolution toward metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT103

The bone remodeling environment is a factor in breast cancer bone metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT103

Inhibitory effect of CT domain of CCN3/NOV on proliferation and differentiation of osteogenic mesenchymal stem cells, Kusa-A1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT103

CCN3 modulates bone turnover and is a novel regulator of skeletal metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT103

Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT103

21 January 2018

Identifiers

DOI

10.1093/CARCIN/BGT103

1 reference

9 September 2017

1 reference